Relaxin
Sponsors
National Center for Research Resources (NCRR), Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, University of Medicine and Dentistry of New Jersey, Cambridge University Hospitals NHS Foundation Trust, Seda KARAKAYA ERGUN
Conditions
Ablation of Atrial FibrillationArrhythmiaAtrial Fibrillation (AF)COPDCardiovascular DiseasesCare BurdenCaregiverCaregiver Burnout
Phase 1
Phase 2
Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
CompletedNCT00004380
Start: 1991-12-31End: 1997-12-31Target: 1Updated: 2005-06-24
A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure
CompletedNCT00259116
Start: 2005-11-30Target: 18Updated: 2009-04-15
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
CompletedNCT00520806
Start: 2007-10-31End: 2012-09-30Updated: 2012-10-30
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin
Active, not recruitingNCT03449251
Start: 2018-03-28End: 2025-09-30Target: 170Updated: 2024-02-07
Phase 3
Unknown Phase
Effect of Autogenic Relaxation Therapy on Caregivers on Perceived Stress Quality of Life and Caregiver Burden
Active, not recruitingNCT06687486
Start: 2024-11-07End: 2025-02-20Target: 64Updated: 2024-11-13
Relaxin and Placental Volume in Placenta Accreta Spectrum
CompletedNCT06808165
Start: 2022-01-01End: 2023-01-01Updated: 2025-02-05
Progressive Relaxation for COPD: Effects on Insomnia and Satisfaction
Active, not recruitingNCT06933602
Start: 2025-02-01End: 2025-12-30Target: 70Updated: 2025-08-24